Background Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into
adolescence, little is known about the efficacy and tolerability of stimulant medications in this …

Objective. OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant
medication used to treat attention-deficit/hyperactivity disorder (ADHD). This study was …

Objective. A new once-a-day methylphenidate (MPH) formulation, Concerta
(methylphenidate HCl) extended-release tablets (OROS MPH), has been developed. This …

Objective: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil
Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the …

OBJECTIVE: Few studies have assessed effectiveness and tolerability of stimulants when
used for prolonged periods in children with attention-deficit/hyperactivity disorder (ADHD) …

OBJECTIVE: Few treatment studies of attention-deficit/hyperactivity disorder (ADHD) extend
beyond a few months. This article reports an interim analysis of a 24-month study evaluating …

This 8-week, open-label extension of a double-blind study reports on safety data for 171
adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily …

This community-based study was designed to evaluate treatment outcomes with OROS®
methylphenidate (MPH) and atomoxetine in children with attentiondeficit/hyperactivity …

Background The thrice daily dosing regimen of immediate release methylphenidate (IR-
MPH) for Attention Deficit/Hyperactivity Disorder (ADHD) requires in-school dosing, leading …

This study examined the efficacy and safety of osmotic release oral system methylphenidate
(OROS MPH) as compared with immediate-release MPH (IR MPH) in children with attention …